Guidance Archives - Page 67 of 637

1 minute read

Honeywell Reiterates FY2024 Outlook: Adj EPS $9.80-10.10 vs $9.95 Est; Sees Sales $38.100B-38.900B vs $38.48B Est

By Benzinga Newsdesk

Yesterday, 6:05 AM

TABLE 1: FULL-YEAR 2024 GUIDANCE2 Previous Guidance Current Guidance Sales $38.1B -

HON

2 minute read

Barclays Reiterated 2024 Outlook: Targets Barclays Group NII Excluding Barclays Investment Bank And Head Office Of £10.7B, Expects RoTE Of Greater Than 10% In 2024 And 10.5% Excluding Inorganic Activity

By Benzinga Newsdesk

Yesterday, 4:22 AM

Group Financial Targets and Outlook: 2024 • Returns: targeting RoTE of greater than 10% and c.10.5% excluding inorganic activity • Income: targeting Barclays Group NII excluding IB and Head Office of

BCS

1 minute read

Essential Properties Realty Trust Updates 2024 AFFO Guidance To $1.72-$1.75 per Share

By Benzinga Newsdesk

April 24, 4:35 PM

2024 GuidanceThe Company has increased the low end of its previously issued fully diluted 2024 AFFO per share estimate and now expects that 2024 AFFO per share on a fully diluted basis will be within a range of $1.72 to

EPRT

1 minute read

Impinj Sees Q2 GAAP EPS $0.20-$0.25 Vs $0.19 Est.; Non-GAAP EPS $0.72-$0.77; Revenue $96M-$99M Vs $78.93M Est.

By Benzinga Newsdesk

April 24, 4:33 PM

Second Quarter 2024 Financial OutlookImpinj provides guidance based on current market conditions and expectations; actual results may differ materially. Please refer to the comments below regarding forward-looking

1 minute read

Biomarin Pharmaceutical Raises FY2024 Adj EPS Guidance From $2.60-2.80 To $2.75-2.95 Vs $1.65 Est; Affirms FY2024 Sales Guidance from $2.70B-2.80B Vs $2.77B Est

By Benzinga Newsdesk

April 24, 4:27 PM

2024 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated)BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking

BMRN

2 minute read

Whirlpool Sees FY24 Ongoing EPS $13.00-$15.00 Vs $13.24 Est.; Revenue ~$16.9B Vs $16.84B

By Benzinga Newsdesk

April 24, 4:14 PM

FULL-YEAR 2024 OUTLOOKGuidance Summary2023 Reported2023 Like forLike (5)2024 GuidanceNet sales ($M)$19,455~$16,900~$16,900Cash provided by operating activities($M)$915N/A$1,150 - $1,250Free cash flow ($M)(3)$366N/A$550 -

WHR

2 minute read

Humana Withdraws Its Already Lowered 2025 Profit Guidance

By Vandana Singh

April 24, 2:18 PM

Humana revises 2025 profit forecast due to disappointing Medicare Advantage reimbursement rates. Medical benefit ratio up to 88.9% in Q1 2024. Adjusted EPS growth outlook impacted by pricing decisions for 2025 MA bids.

HUM

1 minute read

Why Is Norfolk Southern Stock Taking A Hit Today?

By Lekha Gupta

April 24, 1:13 PM

Norfolk Southern shares drop after disappointing Q1 results, with revenue down 4% and expenses up 15%. Quarterly dividend declared.

FTXR

1 minute read

Boston Scientific Lifts 2024 Profit Forecast On Strong Growth From Cardiovascular Devices, Stock Soars

By Vandana Singh

April 24, 12:42 PM

Boston Scientific reports impressive Q1 earnings, with revenues of $3.86 billion, beating estimates. Cardiovascular segment leads with $2.4 billion sales, up 15.9%. Outlook: 2024 net sales growth forecasted at 11%-13%, adjusted EPS at $2.29-$2.34.

BSX

1 minute read

Why Industrial Conglomerate Fortive’s Shares Are Sliding Today

By Lekha Gupta

April 24, 12:19 PM

Fortive reported lower Q1 FY24 results, missing revenue estimates. Adjusted EPS beat expectations. Dividend declared. Fortive revised its FY24 outlook.

BAMG